Rosetta issued patent relating to MicroRNAs.(Company overview) From: BIOTECH Patent News | Date: July 1, 2007 | COPYRIGHT 2007 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

Rosetta Genomics, Ltd. (Rehovot, Israel), a global leader in the field of microRNA and RNAi, announced that on July 31, 2007, the United States Patent and Trademark Office issued Rosetta Genomics United States Patent 7,250,496. The patent, relating to a human microRNA miR-492, is the second composition-of-matter patent that the United States Patent and Trademark Office has issued to Rosetta Genomics but is the first patent issued to it related to a human microRNA. The first microRNA gene patent ever issued worldwide was issued to Rosetta Genomics by the United States Patent and ...

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

	Rosetta Genomics pricing expected tomorrow: The company plans to raise $33-39 million at a company value of $116-137 million. ; Byline: Tali Tsipori Oct. 3--Rosetta Genomics Ltd. is set to float on Nasdaq ahead...will be traded under the ticker ROSG. Rosetta Genomics conducts research into microRNA for...most promising start-up in 2005. If Rosetta Genomics completes its Nasdaq IPO as planned...
	NYU Medical Center Teams With Rosetta Genomics to Develop a microRNA- Based Diagnostic Test for Melanoma ; ...Center Teams With Rosetta Genomics to Develop a microRNA...Center Teams With Rosetta Genomics to Develop a microRNA-Bas...www.10meters.com Rosetta Genomics, a company in the...test for melanoma. Rosetta Genomics believes its unique...submitted a series of patent ...
	Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists. ; Rosetta Genomics, Ltd. (Rehovot, Israel), announced...cancer of unknown primary (CUP). Rosetta Genomics is currently developing a technology...Amir Avniel, President and CEO of Rosetta Genomics. This research demonstrates the...
	Report: Rosetta Genomics Nasdaq IPO hits snags: The company value for the IPO may be cut, or it may be postponed. ; ...Tsipori Oct. 9--The Nasdaq IPO of Rosetta Genomics Ltd. is reportedly not going according...IPOhome provides further evidence of Rosetta Genomics' problems in becoming a public company...share. It will not be a surprise if Rosetta Genomics fails to complete its IPO as planned...
	Rosetta Genomics underwriters exercise green shoe option: 562,500 shares were sold for $3.66 million. ; Byline: Gali Weinreb Mar. 8--Rosetta Genomics Ltd. (Nasdaq:ROSG) has closed the...Including the green shoe option, Rosetta Genomics issued a total of 4.3 shares for total...and net proceeds of $26.2 million. Rosetta Genomics is currently traded at $8.27, up from...
	US Genomics and Rosetta Genomics are collaborating to develop a microRNA-based.(Life Science Instruments: Company Announcements) ; US Genomics and Rosetta Genomics are collaborating to develop a microRNA-based, noninvasive early detection test for lung cancer.
	Rosetta Genomics signs agreement with Max Planck Society: The agreement will give the company access to patents covering hundreds of human microRNA sequences in diagnostic applications. ; Byline: Gali Weinreb Jul. 30--Rosetta Genomics Ltd. has signed a licensing agreement...diagnostic applications. In exchange, Rosetta Genomics will pay the Max Planck Society royalties...sequences. The agreement is similar to Rosetta Genomics microRNA licensing agreement signed...
	IPR push sees patent applications rise ; ...rights (IPRs) protection, with patent applications increasing by over 20 per...attached great importance to patent applications, the SIPO said. In 2005, the SIPO received 476,264 patent applications, according to its annual...
	Rosetta Genomics IPO raises $26.3m: The flotation was priced at $7 per share, $0.50 below the estimated price range. ; Byline: Tali Tsipori Feb. 27--Israeli biotech company Rosetta Genomics has completed its IPO on Nasdaq, raising $26.3 million...offering with Oppenheimer & Co. Inc. as co-manager. Rosetta Genomics has developed a unique computerized algorithm for researching...
	ITALPAT released on Questel. (Italian Patent Applications database) ; ...the ITALPAT (Italian Patent Applications) database, produced...ITALPAT covers all Italian Patent applications (brevetti), utility...utilita) and design patent applications (modello ornamentale...

For more facts and information, see all results